PSFL2915 is a P2X receptor inhibitor with oral effectiveness, with an IC50 of 0.319 µM for human P2X3, 0.261 µM for rat P2X2/3, and 13.3 µM for human P2X2, and exhibits ~42-fold selectivity for human P2X3 over human P2X2. PSFL2915 inhibits human P2X3 activation by preventing allosteric tightening of the inner pocket of the head domain required for channel opening, with magnesium-dependent inhibition. PSFL2915 inhibits rat P2X2/3 and human P2X2 receptor activation, and has low activity against human P2X1, P2X4, and P2X7 receptors. PSFL2915 can be used for the research of chronic cough[1].
Molekulargewicht:
462.36
CAS Nummer:
[88134-39-8]
Formel:
C15H10O13S2
Target-Kategorie:
P2X Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
